Reviewing Unity Biotechnology Inc. (UBX)’s and Cleveland BioLabs Inc. (NASDAQ:CBLI)’s results

Both Unity Biotechnology Inc. (NASDAQ:UBX) and Cleveland BioLabs Inc. (NASDAQ:CBLI) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Unity Biotechnology Inc. 1.38M 350.34 67.03M -6.20 0.00
Cleveland BioLabs Inc. 1.77M 9.88 4.35M -0.39 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us Unity Biotechnology Inc. and Cleveland BioLabs Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Unity Biotechnology Inc. -4,857.25% 0% 0%
Cleveland BioLabs Inc. -245.76% -734.3% -56.6%

Liquidity

15.4 and 15.4 are the respective Current Ratio and a Quick Ratio of Unity Biotechnology Inc. Its rival Cleveland BioLabs Inc.’s Current and Quick Ratios are 3.5 and 3.5 respectively. Unity Biotechnology Inc. has a better chance of clearing its pay short and long-term debts than Cleveland BioLabs Inc.

Insider and Institutional Ownership

Unity Biotechnology Inc. and Cleveland BioLabs Inc. has shares owned by institutional investors as follows: 30.3% and 6%. 0.2% are Unity Biotechnology Inc.’s share owned by insiders. Insiders Comparatively, owned 58.15% of Cleveland BioLabs Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Unity Biotechnology Inc. 10.89% 19.23% -23.21% -5.06% 0% -14.35%
Cleveland BioLabs Inc. -4.28% 1.7% -1.65% -33.95% -28.69% -55.36%

For the past year Unity Biotechnology Inc.’s stock price has smaller decline than Cleveland BioLabs Inc.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.